Is Trazodone a Controlled Substance? What Patients Need to Know

Most of the questions patients ask about trazodone center on one thing: whether it carries the risks they associate with controlled medications. Opioids. Benzodiazepines. Drugs with high abuse potential and strict prescribing restrictions.

Trazodone is different from all of those.

What This Page Covers

• Whether trazodone is a controlled substance under federal law
• How the DEA classifies drugs as controlled
• Why trazodone falls outside that classification
• How trazodone works
• What it is prescribed for
• Side effects and safety considerations
• The difference between dependence and addiction

Is Trazodone a Controlled Substance?

No. Trazodone is not a controlled substance.

The FDA drug label explicitly states that trazodone hydrochloride tablets are not a controlled substance. The DEA does not place trazodone in any schedule under the Controlled Substances Act. It does not require DEA registration or special prescribing authorization beyond a standard prescription.

This is a meaningful distinction for patients. Controlled substances require providers to follow additional prescribing restrictions, and some carry higher risks of abuse, dependence, and regulatory scrutiny. Trazodone sits outside that framework.

“When a patient asks whether trazodone is controlled, what they’re usually asking is: should I be worried about taking this? The answer is that trazodone has a well-established safety profile and a low potential for abuse,” says Daniel Montville, MD, Psychiatrist, of the SiggyMD clinical team. “That said, low abuse potential doesn’t mean zero risk. It’s still a prescription medication with real side effects, real drug interactions, and a need for proper prescriber oversight.”

How the DEA Classifies Controlled Substances

The Controlled Substances Act (CSA) places drugs into five schedules based on two factors: their accepted medical use and their potential for abuse or dependence.

Schedule I substances have no accepted medical use and a high potential for abuse (heroin, LSD). Schedule II substances have accepted medical uses but high abuse potential (oxycodone, stimulants used for ADHD). Schedules III through V cover progressively lower abuse potential, from anabolic steroids (III) to some cough preparations containing low doses of codeine (V).

Trazodone has legitimate medical uses and clinical evidence showing low addiction potential, so it is not regulated under any federal or state schedule. Clinical studies have not demonstrated drug-seeking behavior or significant abuse risk in patients taking trazodone for depression or anxiety.

How Trazodone Works

Trazodone belongs to a class called serotonin antagonist and reuptake inhibitors (SARIs). Unlike SSRIs, which primarily block the reuptake of serotonin from the synaptic cleft, trazodone has a broader pharmacodynamic profile.

At therapeutic doses, trazodone blocks 5-HT2A and 5-HT2C serotonin receptors, histamine H1 receptors, and alpha-1 adrenergic receptors. At higher doses used to treat depression, it also inhibits the serotonin transporter (SERT). The blockade of histamine and alpha-1 receptors is what accounts for its sedative effects, which is why it is frequently prescribed off-label for sleep despite being an antidepressant.

This mechanism distinguishes trazodone from benzodiazepines, which work on GABA receptors and carry a higher risk of dependence. Trazodone does not activate opioid receptors and does not produce the euphoria that characterizes addictive substances.

What Trazodone Treats

FDA-Approved Use

Trazodone is FDA-approved for major depressive disorder (MDD). At antidepressant doses of 150 to 600 mg per day, trazodone is effective for depression with insomnia, anxiety features, and depression in older adults. Its sedating properties, which can be a side effect concern in other contexts, are often clinically useful in patients with depression-related sleep disruption.

Off-Label Uses

Trazodone is among the most frequently prescribed off-label sleep aids in the United States. At lower doses of 25 to 100 mg at bedtime, its antihistamine and alpha-adrenergic blocking effects produce sedation without the controlled-substance concerns associated with benzodiazepine hypnotics or Z-drugs.

However, trazodone’s evidence base for insomnia is limited. The American Academy of Sleep Medicine explicitly recommends against trazodone for sleep onset or sleep maintenance insomnia in adults, citing modest improvements in sleep parameters and insufficient evidence that benefits outweigh risks. Prescribers often reach for it because it is not a controlled substance, not because it has superior insomnia data.

Trazodone may also be prescribed off-label for anxiety disorders, post-traumatic stress disorder, and chronic pain, though evidence varies for each use case.

Trazodone Side Effects and Safety

Common side effects of trazodone include:

• Daytime drowsiness (the most common complaint, especially with morning dosing)
• Dizziness or lightheadedness
• Dry mouth
• Nausea
• Headache
• Blurred vision

Most of these side effects are dose-related and improve with dose adjustment or time. Taking trazodone with food reduces nausea significantly.

Rare but serious side effects include:

Priapism. Prolonged, painful erections unrelated to sexual stimulation can occur in men taking trazodone. This is a medical emergency requiring immediate treatment. The risk is estimated at 1 in 6,000 male patients.

Serotonin syndrome. Combining trazodone with other serotonergic medications (MAOIs, other SSRIs, lithium, certain pain medications) can produce serotonin syndrome, a potentially life-threatening condition characterized by agitation, high temperature, rapid heart rate, and muscle rigidity. Patients should always disclose all medications to their prescriber before starting trazodone.

Cardiac effects. Trazodone can affect cardiac conduction at higher doses. Patients with pre-existing cardiac conditions should be evaluated before starting treatment.

Low blood pressure. Alpha-1 receptor blockade can cause orthostatic hypotension, the experience of dizziness or faintness when standing. Older adults are at higher risk and should rise slowly from sitting or lying positions.

Dependence vs. Addiction: An Important Distinction

Physical dependence and addiction are not the same thing, but they are frequently confused.

Physical dependence occurs when the body adapts to a medication and produces withdrawal symptoms if it is stopped abruptly or tapered too quickly. Trazodone can cause physical dependence with long-term use. Withdrawal symptoms may include dizziness, nausea, irritability, and rebound insomnia.

Addiction involves compulsive drug-seeking behavior, loss of control over use, and continued use despite harm. Clinical evidence does not support trazodone as causing addiction in this sense. Patients do not typically develop drug-seeking behavior with trazodone.

What this means practically: if you have been taking trazodone for an extended period and want to stop, do not stop abruptly. Work with your prescriber on a gradual taper. This is true regardless of whether the underlying condition has resolved.

How SiggyMD Approaches Medication Management

When a prescriber at SiggyMD reviews your intake, they see the full picture: your symptoms, your symptom history, your goals, and any medications or substances that could affect prescribing decisions. For patients with depression and anxiety, the conversation about medication often includes a discussion of what your sleep looks like, whether sedation is clinically useful or a concern, and what medication history you bring with you.

Trazodone is one option in that conversation. What distinguishes SiggyMD’s approach is that the conversation does not end at the prescription. Daily check-ins after you start a medication track how it is actually affecting you, including whether side effects like daytime drowsiness are manageable or need a dose adjustment, and whether the intended clinical benefit is developing on schedule.

No medication is prescribed without a licensed prescriber reviewing your complete intake. The anonymous process means no waiting room, no phone calls, and no barriers to starting that conversation honestly.

For more on how antidepressants work and what the first weeks of treatment typically look like, see our guides on how antidepressants work in the first 8 weeks and a complete list of SSRIs, SNRIs, and atypical antidepressants.

Start your anonymous intake with SiggyMD and connect with a licensed prescriber who reviews your complete picture before anything is prescribed.

What Members Are Saying

JM

J.M., 38

Depression with Sleep Disturbance

“I’d been prescribed trazodone by a previous provider for sleep, and when I moved to SiggyMD I had a lot of questions about whether I should stay on it. My prescriber walked through the actual evidence base, what trazodone is and isn’t good for, and what my other options were. I didn’t feel rushed. I felt like I had a real clinician looking at my full picture.”

PW

P.W., 45

Major Depressive Disorder

“I kept reading online that trazodone was a controlled substance and getting confused about what I was taking. Having a prescriber who could explain the classification, the mechanism, and what to watch for made me much more comfortable actually staying on the medication long enough to see if it worked.”

Member stories reflect real experiences. Names and identifying details have been changed to protect privacy. Results vary.

Sources

1. U.S. Food and Drug Administration. Desyrel (trazodone hydrochloride) Prescribing Information. Revised June 2017.

2. U.S. Drug Enforcement Administration. 2020 Drugs of Abuse: A DEA Resource Guide. DEA. 2020.

3. Jaffer KY, Chang T, Vanle B, et al. Trazodone for Insomnia: A Systematic Review. Innov Clin Neurosci. 2017;14(7-8):24-34.

4. Sateia MJ, Buysse DJ, Krystal AD, et al. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An AASM Clinical Practice Guideline. J Clin Sleep Med. 2017;13(2):307-349.

5. National Institute of Mental Health. Depression. Revised 2024.

6. Jarema M, et al. Trazodon: the antidepressant mechanism of action and its position in the treatment of depression. Psychiatr Pol. 2011;45(4):611-25.

7. MedlinePlus. Trazodone. Updated 2024.